Sector News

Gilead Sciences Acquires EpiTherapeutics

May 7, 2015
Life sciences
(BUSINESS WIRE) – Gilead Sciences, Inc. and EpiTherapeutics ApS, a privately-held Danish company, announced the signing of a definitive agreement pursuant to which Gilead has acquired EpiTherapeutics for $65 million, subject to certain purchase price adjustments, to be financed through available cash on hand.
 
EpiTherapeutics has generated a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. The company’s lead pre-clinical compounds are being studied for the treatment of certain cancers.
 
“Epigenetics is a promising area of research and the EpiTherapeutics team is a recognized scientific leader in this field,” said Norbert Bischofberger, PhD, Gilead’s Executive Vice President, Research and Development and Chief Scientific Officer. “This therapeutic class represents a strategic fit with our existing research portfolio, including the potential for novel combination approaches. We look forward to working with colleagues from EpiTherapeutics to advance these programs toward clinical development in diseases with significant unmet medical need.”
 
“EpiTherapeutics has done groundbreaking work in a new therapeutic class of small molecule inhibitors with broad implications across various disease states,” said Martin Bonde, PhD, EpiTherapeutics’ Chief Executive Officer. “We are confident that with Gilead’s acquisition of the company, our discoveries will have the best chance to be developed into therapies that will benefit patients.”
 
Investors in EpiTherapeutics are NOVO Seeds, SEED Capital, Lundbeckfond Emerge, MS Ventures and Astellas Venture. Back Bay Life Science Advisors of Boston advised EpiTherapeutics on the transaction.
 
Source: Gilead Sciences

comments closed

Related News

September 29, 2024

BMS wins approval for schizophrenia drug acquired from Karuna

Life sciences

The novel drug – named Cobenfy – introduces a new mechanism of action to the schizophrenia treatment landscape by targeting cholinergic receptors as opposed to dopamine receptors. The market for schizophrenia drugs has long been dominated by dopamine-blocking antipsychotics, which are associated with significant side effects such as Parkinsonian symptoms, sexual dysfunction, and weight gain.

September 29, 2024

EC authorises LEO Pharma Anzupgo cream for chronic hand eczema

Life sciences

The European Commission (EC) has granted marketing authorisation to Leo Pharma’s Anzupgo (delgocitinib) cream for treating adults with moderate to severe chronic hand eczema (CHE). The cream is indicated for use in CHE patients for whom topical corticosteroids are not suitable.

September 29, 2024

Months after Frank Nestle’s departure, Sanofi selects new CSO

Life sciences

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi. Quigley will start Sept. 30 as the French Big Pharma’s chief scientific officer and global head of research, Sanofi told Fierce Biotech in an emailed statement.